Skip to main content
. 2001 Mar;51(3):201–208. doi: 10.1046/j.1365-2125.2001.00321.x

Table 2.

Percentage improvements in ACR response from baseline for infliximab and placebo at 30 weeks [25].

Index Placebo Infliximab 3 mg kg−1/4 weeks (P values vs placebo) 3 mg kg−1/8 weeks 10 mg kg−1/4 weeks 10 mg kg−1/8 weeks
ACR20 20% 53% 50% 58% 52%
(P < 0.001) (P < 0.001) (P < 0.001) (P < 0.001)
ACR50 5% 29% 27% 26% 31%
(P < 0.001) (P < 0.001) (P < 0.001) (P < 0.001)
ACR70 0% 11% 8% 11% 18%
(P < 0.001) (P = 0.002) (P = 0.007) (P = 0.002)